TriSalus Life Sciences, Inc. - TLSI
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Apr 01, 2026 | — | C | D | 100,000.0 | 0.0 | 0.0 | 0.0 | View | |
| Apr 01, 2026 | — | C | A | 330,000.0 | 0.0 | 0.0 | 1,271,944.0 | View | |
| Mar 20, 2026 | Chief Regulatory Officer | S | D | 774.0 | 4.12 | 3,188.88 | 124,110.0 | View | |
| Mar 20, 2026 | Chief Regulatory Officer | S | D | 1,552.0 | 4.09 | 6,347.68 | 124,884.0 | View | |
| Mar 20, 2026 | Chief Regulatory Officer | S | D | 1,204.0 | 4.13 | 4,972.52 | 126,436.0 | View | |
| Mar 20, 2026 | Chief Commercial Officer | S | D | 419.0 | 4.12 | 1,726.28 | 110,397.0 | View | |
| Mar 20, 2026 | Chief Commercial Officer | S | D | 1,589.0 | 4.09 | 6,499.01 | 110,816.0 | View | |
| Mar 20, 2026 | Chief Commercial Officer | S | D | 1,449.0 | 4.13 | 5,984.37 | 112,405.0 | View | |
| Mar 20, 2026 | Chief of Research | S | D | 579.0 | 4.12 | 2,385.48 | 163,415.0 | View | |
| Mar 20, 2026 | Chief of Research | S | D | 1,467.0 | 4.09 | 6,000.03 | 163,994.0 | View | |
| Mar 20, 2026 | Chief of Research | S | D | 1,138.0 | 4.13 | 4,699.94 | 165,461.0 | View | |
| Mar 20, 2026 | Chief of Clinical Operations | S | D | 273.0 | 4.12 | 1,124.76 | 97,364.0 | View | |
| Mar 20, 2026 | Chief of Clinical Operations | S | D | 1,772.0 | 4.09 | 7,247.48 | 97,637.0 | View | |
| Mar 20, 2026 | Chief of Clinical Operations | S | D | 1,162.0 | 4.13 | 4,799.06 | 99,409.0 | View | |
| Mar 20, 2026 | CEO and President | S | D | 15,944.0 | 3.85 | 61,384.4 | 752,987.0 | View | |
| Mar 20, 2026 | CEO and President | S | D | 4,358.0 | 4.13 | 17,998.54 | 768,931.0 | View | |
| Feb 23, 2026 | CEO and President | P | A | 30,487.0 | 4.1 | 124,996.7 | 773,289.0 | View | |
| Feb 23, 2026 | — | P | A | 30,487.0 | 4.1 | 124,996.7 | 30,487.0 | View | |
| Feb 23, 2026 | — | P | A | 9,756.0 | 4.1 | 39,999.6 | 9,756.0 | View | |
| Feb 23, 2026 | Chief Financial Officer | P | A | 3,657.0 | 4.1 | 14,993.7 | 268,657.0 | View | |
| Feb 23, 2026 | — | P | A | 117,198.0 | 4.1 | 480,511.8 | 199,698.0 | View | |
| Feb 23, 2026 | — | P | A | 243,900.0 | 4.1 | 999,990.0 | 787,132.0 | View | |
| Feb 11, 2026 | — | A | A | 92,537.0 | 0.0 | 0.0 | 92,537.0 | View | |
| Nov 25, 2025 | Chief of Research | A | A | 80,000.0 | 0.0 | 0.0 | 261,954.0 | View | |
| Nov 25, 2025 | Chief of Research | A | A | 40,000.0 | 0.0 | 0.0 | 166,599.0 | View | |
| Nov 25, 2025 | Chief Commercial Officer | A | A | 120,000.0 | 0.0 | 0.0 | 408,937.0 | View | |
| Nov 25, 2025 | Chief Commercial Officer | A | A | 60,000.0 | 0.0 | 0.0 | 113,854.0 | View | |
| Nov 25, 2025 | Chief Regulatory Officer | A | A | 100,000.0 | 0.0 | 0.0 | 323,782.0 | View | |
| Nov 25, 2025 | Chief Regulatory Officer | A | A | 50,000.0 | 0.0 | 0.0 | 127,640.0 | View | |
| Nov 25, 2025 | CEO and President | A | A | 250,000.0 | 0.0 | 0.0 | 1,578,182.0 | View | |
| Nov 25, 2025 | CEO and President | A | A | 300,000.0 | 0.0 | 0.0 | 742,802.0 | View | |
| Nov 25, 2025 | CEO and President | A | A | 125,000.0 | 0.0 | 0.0 | 442,802.0 | View | |
| Nov 25, 2025 | CEO and President | A | A | 125,000.0 | 0.0 | 0.0 | 317,802.0 | View | |
| Nov 25, 2025 | Chief of Clinical Operations | A | A | 100,000.0 | 0.0 | 0.0 | 463,750.0 | View | |
| Nov 25, 2025 | Chief of Clinical Operations | A | A | 50,000.0 | 0.0 | 0.0 | 100,571.0 | View | |
| Nov 25, 2025 | Chief Financial Officer | A | A | 130,000.0 | 0.0 | 0.0 | 668,899.0 | View | |
| Nov 25, 2025 | Chief Financial Officer | A | A | 65,000.0 | 0.0 | 0.0 | 265,000.0 | View |